157 related articles for article (PubMed ID: 11000679)
1. [Monitoring drug ototoxicity with distortion products].
Orts Alborch M; Morant Ventura A; García Callejo J; Ferrer Baixauli F; Martínez Beneito MP; Marco Algarra J
Acta Otorrinolaringol Esp; 2000; 51(5):387-95. PubMed ID: 11000679
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study on the ototoxicity of cisplatin with distortion products].
Orts Alborch M; García Callejo J; Morant Ventura A; Ferrer Baixauli F; Esparcia Navarro M; Marco Algarra J
Acta Otorrinolaringol Esp; 2000; 51(6):469-77. PubMed ID: 11142781
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
4. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
5. [Hearing evaluation in children during chemotherapy].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Pol Merkur Lekarski; 2005 Sep; 19(111):340-2. PubMed ID: 16358863
[TBL] [Abstract][Full Text] [Related]
6. Outer hair cell activity of the cochlea in patients with iron deficiency anemia.
Cetin T; Yetiser S; Cekin E; Durmus C; Nevruz O; Oktenli C
Auris Nasus Larynx; 2004 Dec; 31(4):389-94. PubMed ID: 15571912
[TBL] [Abstract][Full Text] [Related]
7. Distortion-product otoacoustic emission spectra and high-resolution audiometry in noise-induced hearing loss.
Avan P; Bonfils P
Hear Res; 2005 Nov; 209(1-2):68-75. PubMed ID: 16112827
[TBL] [Abstract][Full Text] [Related]
8. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions.
Katbamna B; Homnick DN; Marks JH
Ear Hear; 1999 Oct; 20(5):393-402. PubMed ID: 10526861
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cochlear hearing disorders: normative distortion product otoacoustic emission measurements.
Mills DM; Feeney MP; Gates GA
Ear Hear; 2007 Dec; 28(6):778-92. PubMed ID: 17982366
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions.
Riga M; Korres S; Psarommatis I; Varvutsi M; Giotakis I; Papadas T; Ferekidis E; Apostolopoulos N
Otol Neurotol; 2007 Feb; 28(2):208-12. PubMed ID: 17255889
[TBL] [Abstract][Full Text] [Related]
11. Otoacoustic emissions in patients with hypotension.
Balatsouras DG; Korres S; Simaskos N; Kandiloros D; Ferekidis E; Economou C
J Laryngol Otol; 2003 Apr; 117(4):265-9. PubMed ID: 12816214
[TBL] [Abstract][Full Text] [Related]
12. Chirp-Evoked Otoacoustic Emissions and Middle Ear Absorbance for Monitoring Ototoxicity in Cystic Fibrosis Patients.
Garinis AC; Keefe DH; Hunter LL; Fitzpatrick DF; Putterman DB; McMillan GP; Gold JA; Feeney MP
Ear Hear; 2018; 39(1):69-84. PubMed ID: 28708814
[TBL] [Abstract][Full Text] [Related]
13. Distortion product of otoacoustic emissions as a sensitive indicator of hearing loss in pilots.
Zhang Y; Zhang X; Zhu W; Zheng X; Deng X
Aviat Space Environ Med; 2004 Jan; 75(1):46-8. PubMed ID: 14736132
[TBL] [Abstract][Full Text] [Related]
14. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
15. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions.
Riga M; Psarommatis I; Korres S; Lyra Ch; Papadeas E; Varvutsi M; Ferekidis E; Apostolopoulos N
Int J Pediatr Otorhinolaryngol; 2006 Jun; 70(6):1003-8. PubMed ID: 16359737
[TBL] [Abstract][Full Text] [Related]
16. Hearing loss in cystic fibrosis.
Martins LM; Camargos PA; Becker HM; Becker CG; Guimarães RE
Int J Pediatr Otorhinolaryngol; 2010 May; 74(5):469-73. PubMed ID: 20189661
[TBL] [Abstract][Full Text] [Related]
17. [Examinations of distortion product otoacoustic emission in hereditary progressive non-syndromic hearing loss].
Ke X; Yu H; Liu Y; Gu Z; Lu Y; Li L
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Apr; 35(2):102-4. PubMed ID: 12768663
[TBL] [Abstract][Full Text] [Related]
18. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment.
Toral-Martiñón R; Shkurovich-Bialik P; Collado-Corona MA; Mora-Magaña I; Goldgrub-Listopad S; Shkurovich-Zaslavsky M
Arch Med Res; 2003; 34(3):205-8. PubMed ID: 14567400
[TBL] [Abstract][Full Text] [Related]
19. Aminoglycoside ototoxicity.
Zheng Y; Schachern PA; Sone M; Papapella MM
Otol Neurotol; 2001 Mar; 22(2):266-8. PubMed ID: 11300281
[No Abstract] [Full Text] [Related]
20. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
